P2RY12 and coronary artery disorder: Aspirin has been shown to be superior to placebo for long-term maintenance therapy, but has lower efficacy compared to P2Y12 inhibitors for secondary prevention after stent placement for STEMI, NSTEMI, or stable CAD.